Intraperitoneal injection of ginkgolide B, a major active compound of Ginkgo biloba, dose-dependently increases the amount of wake and decreases non-rapid eye movement sleep in C57BL/6 mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Scientific Publishers Ireland Country of Publication: Ireland NLM ID: 7600130 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7972 (Electronic) Linking ISSN: 03043940 NLM ISO Abbreviation: Neurosci Lett Subsets: MEDLINE
    • Publication Information:
      Publication: Limerick : Elsevier Scientific Publishers Ireland
      Original Publication: Amsterdam, Elsevier/North-Holland.
    • Subject Terms:
      Ginkgo biloba*; Ginkgolides/*administration & dosage ; Lactones/*administration & dosage ; Plant Extracts/*administration & dosage ; Sleep Stages/*drug effects ; Wakefulness/*drug effects; Animals ; Cyclopentanes/administration & dosage ; Dose-Response Relationship, Drug ; Electroencephalography/drug effects ; Furans/administration & dosage ; Injections, Intraperitoneal/methods ; Male ; Mice ; Mice, Inbred C57BL ; Sleep Stages/physiology ; Wakefulness/physiology
    • Abstract:
      The terpene lactones of Ginkgo biloba extract, namely ginkgolides (A, B, and C) and bilobalide, possess antioxidant, anti-inflammatory, and neuroprotective effects. They are widely prescribed for the treatment of cerebral dysfunctions and neurological impairments. In addition, they demonstrate antagonistic action at the gamma-aminobutyric acid type A and glycine receptors, which are members of the ligand-gated ion channel superfamily. In the present study, the effects of ginkgolides (A, B, and C) and bilobalide on sleep in C57BL/6 mice were investigated. Ginkgolide B was found to dose-dependently increase the amount of wake and decrease that of non-rapid eye movement sleep without changes in the electroencephalography power density of each sleep/wake stage, core body temperature and locomotor activity for the first 6 h after intraperitoneal injection. Of note, the amount of wake after injection of 5 mg/kg of ginkgolide B showed a significant increase (14.9 %) compared with that of vehicle (P = 0.005). In contrast, there were no significant differences in the amount of sleep, core body temperature, and locomotor activity in the mice injected with ginkgolide A and C. Bilobalide briefly induced a decrease in locomotor activity but did not exert significant effects on the amounts of sleep and wake. The modes of action of the wake-enhancing effects of ginkgolide B are unknown. However, it may act through the antagonism of gamma-aminobutyric acid type A and glycine receptors because it is established that these inhibitory amino acids mediate sleep and sleep-related physiology. It is of interest to further evaluate the stimulant and awaking actions of ginkgolide B on the central nervous system in clinical and basic research studies.
      Competing Interests: Declaration of Competing Interest All authors declare no conflicts of interest.
      (Copyright © 2020 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Bilobalide; Ginkgolides; Mouse; NREM sleep; Wakefulness
    • Accession Number:
      0 (Cyclopentanes)
      0 (Furans)
      0 (Ginkgolides)
      0 (Lactones)
      0 (Plant Extracts)
      DF149B9460 (ginkgolide B)
      M81D2O8H7U (bilobalide)
    • Publication Date:
      Date Created: 20200213 Date Completed: 20210419 Latest Revision: 20210419
    • Publication Date:
      20240829
    • Accession Number:
      10.1016/j.neulet.2020.134832
    • Accession Number:
      32050100